3,259 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Semmax Financial Advisors Inc.

Semmax Financial Advisors Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,259 shares of the company’s stock, valued at approximately $421,000.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares during the period. Vanguard Group Inc lifted its stake in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares during the period. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 1.9% during the fourth quarter. BlackRock Inc. now owns 182,903,344 shares of the company’s stock valued at $23,603,679,000 after buying an additional 3,486,924 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in shares of Johnson & Johnson by 11,576.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 74,757,633 shares of the company’s stock valued at $579,000 after buying an additional 74,117,373 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 36,364,874 shares of the company’s stock valued at $4,685,372,000 after buying an additional 2,741,351 shares during the period. 66.90% of the stock is currently owned by institutional investors.

In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.23% of the company’s stock.



JNJ has been the topic of several recent analyst reports. Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, May 28th. They set a “buy” rating on the stock. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Wells Fargo & Co reissued an “outperform” rating and set a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Citigroup upped their price objective on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Finally, Raymond James increased their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $147.30.

NYSE:JNJ opened at $141.68 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. The company has a market cap of $371.12 billion, a price-to-earnings ratio of 17.32, a P/E/G ratio of 2.42 and a beta of 0.70. Johnson & Johnson has a fifty-two week low of $120.11 and a fifty-two week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. Johnson & Johnson’s revenue was up .1% on a year-over-year basis. During the same quarter last year, the firm posted $2.06 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th were paid a dividend of $0.95 per share. The ex-dividend date was Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.68%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.

ILLEGAL ACTIVITY WARNING: “3,259 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Semmax Financial Advisors Inc.” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://dakotafinancialnews.com/2019/06/13/3259-shares-in-johnson-johnson-nysejnj-acquired-by-semmax-financial-advisors-inc.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Hedge Funds Explained

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.